Table 2.
Vaccines which obtained or applied for EUA for COVID-19. (current as of 15th Feb, 2021)
| ID | Developer | Formulation Strategies | Countries with EUA | Platform |
|---|---|---|---|---|
| CoronaVac | Sinovac Biotech | Inactivated SARS-CoV-2 using β-propiolactone | China, U.A.E | Inactivated Virus |
| BBIBP-CorV | Beijing Institute of Biological Products; Sinopharm | Inactivated SARS-CoV-2 (vero cell) | China, U.A.E, Bharat | Inactivated Virus |
| Covaxin (BBV152) | Bharat Biotech; Indian Council of Medical Research (ICMR) | Inactivated SARS-CoV-2 vaccine with alum | India | Inactivated Virus |
| NVX-CoV2373 | Novavax | Full-length S-protein nanoparticle with Matrix-M adjuvant | Seeking EUA from FDA | Protein Subunit |
| EpiVacCorona | Vector State Research Center of Virology and Biotechnology | SARS-CoV-2 Peptides | Russia | Peptide |
| mRNA-1273 | Moderna; NIAID | Ionizable Lipid nanoparticle encapsulated mRNA- S protein | US; multiple other countries | mRNA |
| BNT162b2 | BioNTech; Fosun Pharma; Pfizer | b2: Lipid nanoparticles with mRNA- prefusion stabilized S protein | US; multiple other countries | mRNA |
| AZD1222 | University of Oxford; AstraZeneca | chimpanzee adenovirus vector encoded with SARS-CoV-2 S protein | UK; multiple other countries; Halted in South Africa | Viral Vector |
| Ad5-nCoV | CanSino Biological Inc.; Beijing Institute of Biotechnology | Adenovirus type 5- encoded with SARS-CoV-2 S protein | China, Mexico | Viral Vector |
| Sputnik V (Gam-COVID-Vac) | Gamaleya Research Institute | Ad5/Ad26 based vaccine encoding SARS CoV-2 S protein (liquid formulation) | Russia, multiple other countries | Viral Vector |
| Ad26.COV2-S | Janssen Pharmaceutical Companies | Ad26 encoded with SARS-CoV-2 S protein | US, seeking approval in EU and Canada | Viral Vector |